259 related articles for article (PubMed ID: 15230644)
1. Safety profile of tegaserod, a 5-HT4 receptor agonist, for the treatment of irritable bowel syndrome.
Hasler WL; Schoenfeld P
Drug Saf; 2004; 27(9):619-31. PubMed ID: 15230644
[TBL] [Abstract][Full Text] [Related]
2. Review article: the safety profile of tegaserod.
Schoenfeld P
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():25-30. PubMed ID: 15521852
[TBL] [Abstract][Full Text] [Related]
3. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.
Evans BW; Clark WK; Moore DJ; Whorwell PJ
Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807
[TBL] [Abstract][Full Text] [Related]
4. Tegaserod for constipation-predominant irritable bowel syndrome.
Kale-Pradhan PB; Wilhelm SM
Pharmacotherapy; 2007 Feb; 27(2):267-77. PubMed ID: 17253916
[TBL] [Abstract][Full Text] [Related]
5. Tegaserod for the treatment of irritable bowel syndrome.
Evans BW; Clark WK; Moore DJ; Whorwell PJ
Cochrane Database Syst Rev; 2004; (1):CD003960. PubMed ID: 14974049
[TBL] [Abstract][Full Text] [Related]
6. Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women.
Wagstaff AJ; Frampton JE; Croom KF
Drugs; 2003; 63(11):1101-20. PubMed ID: 12749744
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of tegaserod in irritable bowel syndrome management.
Berardi RR
J Am Pharm Assoc (2003); 2004; 44(1):41-51. PubMed ID: 14965152
[TBL] [Abstract][Full Text] [Related]
8. Tegaserod maleate in the treatment of irritable bowel syndrome: a clinical review.
Rivkin A
Clin Ther; 2003 Jul; 25(7):1952-74. PubMed ID: 12946544
[TBL] [Abstract][Full Text] [Related]
9. Tegaserod.
Scott LJ; Perry CM
Drugs; 1999 Sep; 58(3):491-6; discussion 497-8. PubMed ID: 10493276
[TBL] [Abstract][Full Text] [Related]
10. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.
Tack J; Müller-Lissner S; Bytzer P; Corinaldesi R; Chang L; Viegas A; Schnekenbuehl S; Dunger-Baldauf C; Rueegg P
Gut; 2005 Dec; 54(12):1707-13. PubMed ID: 16020489
[TBL] [Abstract][Full Text] [Related]
11. Review of tegaserod in the treatment of irritable bowel syndrome.
Patel S; Berrada D; Lembo A
Expert Opin Pharmacother; 2004 Nov; 5(11):2369-79. PubMed ID: 15500384
[TBL] [Abstract][Full Text] [Related]
12. Benefit-risk assessment of tegaserod in irritable bowel syndrome.
Lea R; Whorwell PJ
Drug Saf; 2004; 27(4):229-42. PubMed ID: 15003035
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity.
Appel-Dingemanse S
Clin Pharmacokinet; 2002; 41(13):1021-42. PubMed ID: 12403641
[TBL] [Abstract][Full Text] [Related]
14. The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies.
Lewis JH
Drug Saf; 2011 Jul; 34(7):545-65. PubMed ID: 21663331
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation.
Fock KM; Wagner A;
J Gastroenterol Hepatol; 2007 Aug; 22(8):1190-8. PubMed ID: 17524039
[TBL] [Abstract][Full Text] [Related]
16. Tegaserod for the Treatment of Irritable Bowel Syndrome.
Madia VN; Messore A; Saccoliti F; Tudino V; De Leo A; De Vita D; Bortolami M; Scipione L; Pindinello I; Costi R; Di Santo R
Antiinflamm Antiallergy Agents Med Chem; 2020; 19(4):342-369. PubMed ID: 31518227
[TBL] [Abstract][Full Text] [Related]
17. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome.
Nyhlin H; Bang C; Elsborg L; Silvennoinen J; Holme I; Rüegg P; Jones J; Wagner A
Scand J Gastroenterol; 2004 Feb; 39(2):119-26. PubMed ID: 15000272
[TBL] [Abstract][Full Text] [Related]
18. [Tegaserod in treatment of women with irritable bowel syndrome].
Munck LK; Ainsworth MA
Ugeskr Laeger; 2007 Jun; 169(23):2190-2. PubMed ID: 17592683
[TBL] [Abstract][Full Text] [Related]
19. Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial.
Foxx-Orenstein AE; Camilleri M; Szarka LA; McKinzie S; Burton D; Thomforde G; Baxter K; Zinsmeister AR
Neurogastroenterol Motil; 2007 Oct; 19(10):821-30. PubMed ID: 17539894
[TBL] [Abstract][Full Text] [Related]
20. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial.
Chey WD; Paré P; Viegas A; Ligozio G; Shetzline MA
Am J Gastroenterol; 2008 May; 103(5):1217-25. PubMed ID: 18477346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
